14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Thu, 2 May 2024

ARQL Predictions History

5 years ago
PumpTheseNumbers predicted that ARQL for 2019-04-08 is going $5.07 (-0.78%)

5 years ago
Gp predicted that ARQL for 2019-04-08 is going $5.15 (0.78%)

5 years ago
ss predicted that ARQL for 2019-04-08 is going $5.02 (-1.95%)

Rank:

5 years ago
PumpTheseNumbers predicted that ARQL for 2019-02-15 is going $3.25 (-4.69%)

5 years ago
JS predicted that ARQL for 2019-02-15 is going $3.18 (-6.74%)

5 years ago
JS predicted that ARQL for 2019-02-15 is going $3.18 (-6.74%)

5 years ago
Joe.Crawford.89897 predicted that ARQL for 2018-10-01 is going $5.77 (1.94%)

Rank:

5 years ago
Mike.Thorne.88713 predicted that ARQL for 2018-09-21 is going $5.13 (-0.39%)

Rank:

5 years ago
Robert predicted that ARQL for 2018-08-13 is going $6.00 (9.89%)

Rank:

5 years ago
Robert predicted that ARQL for 2018-08-10 is going $5.65 (3.48%)

Rank:
Click to get the best stock tips daily for free!

About ArQule

ArQule ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer and non-small cell lung cancer; Phase II clinical trial for the treatment of mesotheli... ARQL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT